Researchers Publish Trial Protocols for Examining Benefits of Hemp Seed Protein on Hypertension
This past week, researchers at the University of Manitoba published clinical trial protocols for a study examining the impacts of hemp seed protein on hypertension in human beings:
Primary hypertension accounts for almost 95% of all cases of high blood pressure and is a major modifiable risk factor for cardiovascular diseases. Lifestyle interventions have been shown to prevent hypertension. One of the prominent potential therapeutic lifestyle strategies to prevent or manage hypertension is increasing dietary protein as a macronutrient or as bioactive peptides. An emerging plant-based protein source that may have anti-hypertensive properties is hemp seed.
Hemp seed (Cannabis sativa L.) utilization into foods has been limited due to legislation restricting the cultivation of all Cannabis species on account of the presence of varieties high in the psychoactive compound tetrahydrocannabinol (THC). However, as of 1998 in Canada, cultivation of hemp seed containing < 0.3% THC has been allowed. Despite heightened consumer demand for hemp food products, due to historical restrictions on the growing of hemp, the nutritional science literature on hemp-seed protein (HSP) remains limited . HSP has a unique amino-acid profile, with high levels of arginine, which makes HSP an ideal protein to consume for BP-reducing effect, or from which to make BP-reducing bioactive peptides .